Story perspectives

Teva Pharmaceuticals Recalls 580,000 Prazosin Capsules Over Carcinogen Risk

11/1/2025

Summary

Story summary

Teva Pharmaceuticals recalled over 580,000 bottles of Prazosin Hydrochloride capsules due to elevated levels of the carcinogenic impurity N-nitroso Prazosin.
The FDA classified this recall as Class II, indicating potential temporary health risks.
The affected capsules, available in 1 mg, 2 mg, and 5 mg doses, have expiration dates from April 2026 to September 2027.
Health experts recommend patients consult their healthcare providers before altering their medication.
Teva stated that alternative hypertension treatments are available and reaffirmed its commitment to product quality and patient safety.

1 of 1

Story summary

Teva Pharmaceuticals recalled over 580,000 bottles of Prazosin Hydrochloride capsules due to elevated levels of the carcinogenic impurity N-nitroso Prazosin.
The FDA classified this recall as Class II, indicating potential temporary health risks.
The affected capsules, available in 1 mg, 2 mg, and 5 mg doses, have expiration dates from April 2026 to September 2027.
Health experts recommend patients consult their healthcare providers before altering their medication.
Teva stated that alternative hypertension treatments are available and reaffirmed its commitment to product quality and patient safety.